Bioventus (NASDAQ:BVS) reported a return to profitability for the full year 2025, supported by a strong fourth-quarter performance that saw organic revenue accelerate across its core healing therapies.
The Durham, North Carolina-based company, which specializes in orthobiologics and active healing, benefited from a strategic restructuring that included the divestiture of its non-core advanced rehabilitation business.
For the fourth quarter ended December 31, 2025, Bioventus posted a net income of $14.8 million, or $0.21 per diluted share.
On an adjusted basis, earnings reached $0.24 per share, surpassing the analyst consensus of $0.22.
Revenue for the period totaled $157.9 million, a 2.8% increase on a reported basis but a robust 10% jump when measured organically.
The growth was led by the Pain Treatments segment, which rose 15.1% to $79.7 million due to high demand for the company’s hyaluronic acid therapies for knee osteoarthritis.
For the full year 2025, Bioventus reported total revenue of $568.1 million.
While reported revenue was essentially flat compared to 2024 due to divestitures, organic revenue for the year grew 7.5%.
The company successfully pivoted from a net loss in 2024 to a net income of $22.7 million, or $0.33 per diluted share, for the full year 2025.
This turnaround was bolstered by an 8.7% reduction in SG&A expenses and the strengthening of the balance sheet through a $29 million debt reduction in the final quarter.
Looking ahead, Bioventus issued fiscal 2026 guidance that projects continued momentum.
The company expects full-year revenue to land between $600 million and $610 million, representing growth of 6% to 7%.
Adjusted earnings are forecast to range from $0.73 to $0.77 per share.